Form 4: United Therapeutics Director Sells Shares Under 10b5-1 Plan

United Therapeutics Director Christopher Causey executed a pre-planned sale of 1,300 common shares following the exercise of stock options.

Summary

• Christopher Causey, a Director at United Therapeutics Corp (UTHR), engaged in a pre-planned transaction on March 30, 2026.
• The transaction involved the exercise of 1,300 stock options at an exercise price of $119.76 per share.
• Immediately following the option exercise, 1,300 shares of common stock were sold at a price of $604.64 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan established on September 30, 2025.
• Following these transactions, Causey directly beneficially owns 4,190 shares of common stock and 5,000 derivative stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It represents a routine, pre-planned insider transaction under a Rule 10b5-1 plan, which is a common practice for managing executive compensation and equity holdings.

Positives

• The execution of a Rule 10b5-1 plan demonstrates structured and pre-planned insider trading, reducing concerns about opportunistic selling.
• The sale price of $604.64 per share is significantly higher than the exercise price of $119.76, indicating a substantial gain for the director on the exercised options.

Negatives

• The sale of shares by a director, even if pre-planned, represents a reduction in their direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common practice for corporate executives and directors to manage their equity holdings in a compliant manner. These pre-arranged plans help mitigate concerns about trading on material non-public information.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine, pre-planned insider transaction. The sale represents a director monetizing a portion of their equity compensation.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, Rule 10b5-1, Director Sale, Equity Transaction, Beneficial Ownership